T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 794.4 INR 0.81% Market Closed
Market Cap: 1.3T INR

Torrent Pharmaceuticals Ltd
PP&E Net

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Torrent Pharmaceuticals Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
PP&E Net
₹39.5B
CAGR 3-Years
6%
CAGR 5-Years
2%
CAGR 10-Years
1%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
PP&E Net
₹111.2B
CAGR 3-Years
21%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
PP&E Net
₹69.4B
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
4%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
PP&E Net
₹117.6B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
1%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
PP&E Net
₹82.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
9%
Lupin Ltd
NSE:LUPIN
PP&E Net
₹55B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
4%
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

In the bustling realm of Indian pharmaceuticals, Torrent Pharmaceuticals Ltd. has carved out a notable niche, emerging from the industrious land of Gujarat. Founded in 1959, this company has transformed from a modest player to a major force in the industry, traversing the complexities of pharmaceutical manufacturing and global distribution. At its core, Torrent Pharmaceuticals is driven by a commitment to healthcare innovation and therapeutic excellence. The company systematically engages in developing, manufacturing, and marketing a wide array of generic pharmaceutical products primarily targeting cardiovascular, central nervous system, gastro-intestinal, anti-infective, and anti-diabetic therapeutic categories. This diverse product portfolio positions Torrent not just as a provider of remedies but as a critical player in improving health outcomes across numerous demographics and geographies. Torrent Pharmaceuticals operates on a robust business model that effectively integrates research, development, and widespread distribution to generate revenue. The company channels significant resources into its R&D capabilities, perpetually expanding its pipeline to introduce more effective and affordable medications. This ongoing innovation supports their competitive edge while fortifying their catalog of offerings. Additionally, Torrent's strategic alliances and acquisitions—most notably, the key acquisition of Elder Pharmaceuticals' branded domestic formulations business in India—have further catapulted its market presence both domestically and internationally. By leveraging its extensive marketing network and manufacturing capabilities compliant with international standards, Torrent not only bankrolls its growth through product sales but also ensures global reach, cementing its role as a pivotal component of the healthcare landscape.

TORNTPHARM Intrinsic Value
2 399.04 INR
Overvaluation 37%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's PP&E Net?
PP&E Net
39.5B INR

Based on the financial report for Sep 30, 2025, Torrent Pharmaceuticals Ltd's PP&E Net amounts to 39.5B INR.

What is Torrent Pharmaceuticals Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
1%

Over the last year, the PP&E Net growth was 9%. The average annual PP&E Net growth rates for Torrent Pharmaceuticals Ltd have been 6% over the past three years , 2% over the past five years , and 1% over the past ten years .

Back to Top